5 Key Takeaways

• 1

  Geographic atrophy (GA) is a major cause of irreversible vision loss in older adults, resulting from progressive retinal damage.

• 2

  Pegcetacoplan and avacincaptad pegol are approved therapies that inhibit complement activation, showing modest reductions in GA lesion growth.

• 3

  Emerging therapies for GA include mitochondrial-targeted treatments, gene therapies, and cell-based approaches aimed at preserving vision.

• 4

  Vonaprument, a monoclonal antibody targeting C1q, is currently in phase 3 trials to assess its efficacy in preventing vision loss.

• 5

  Innovative gene therapies like JNJ-81201887 and CTx001 are being developed to target underlying disease mechanisms in GA.